OR WAIT null SECS
Agnes Shanley is senior editor of BioPharm International.
Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, cost of goods, and sustainability from the start.
Cell therapies, both autologous and allogeneic, have come a long way in just a few years. Failures, often in clinical stages, have been traced to problems with manufacturing and failure to understand process requirements earlier in the development process.